Inovio Pharmaceuticals (INO) Other Operating Expenses (2011 - 2023)

Inovio Pharmaceuticals (INO) posted Other Operating Expenses of $10.5 million for Q3 2023, up 951.34% sequentially from $1.0 million in Q4 2017.

Inovio Pharmaceuticals (INO) Other Operating Expenses (2011 - 2023) Analysis & Trends

Inovio Pharmaceuticals has reported Other Operating Expenses for 7 years, with the latest figure at $10.5 million in Q3 2023.

Quarterly Other Operating Expenses changed N/A year-over-year to $10.5 million in Q3 2023, while the trailing twelve-month figure through Jun 2024 was $10.5 million (changed N/A YoY) and the FY2023 annual result came in at $10.5 million, changed N/A from the prior year.
Other Operating Expenses climbed to $10.5 million in Q3 2023 per INO's latest filing, from $1.0 million in the prior quarter.
Over five years, Other Operating Expenses peaked at $10.5 million in Q3 2023 and troughed at $10.5 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Inovio Pharmaceuticals	96.32 Mn	96.32 Mn	-

Download Data